5-fluorouracil derivatives

US9902752B2 · kind B2 · utility

Assignee

• B. Braun Melsungen AG · DE

Inventors

• Helmut Rosemeyer · Osnabrück, DE
• Edith Malecki · Bad Zwischenahn, DE

Key dates

• Filing date: Sep 25, 2013
• Grant date: Feb 27, 2018
• Expiry date: Nov 26, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention is directed to a compound that can be used in the treatment of cancer. The compound is represented by formula (I)Further, X isIn addition, R1 is selected from H,andsubstituted or unsubstituted cyclic terpene moieties; R7 and R8 are independently selected from C1 to C30 alkyl; n is an integer ranging 1 to 4; and a is an integer ranging from 1 to 20. Moreover, R2 is H; a Mono-phosphate, Di-phosphate, Tri-phosphate or phosphoamidite moiety; or —Y—X1 or —Y-L-Y1—X1, where Y and Y1 are independently from each other a single bond or a functional connecting moiety, X1 is a colloid-active compound, a fluorescence marker, or a polynucleotide moiety having up to 50 nucleotide residues. L is a linker where Y and X1 are covalently linked together; R5 and R6 represent independently from each other a C1-C28-alkyl moiety which may optionally be substituted/interrupted by one or more heteroatom(s) and/or functional group(s); a C1-C28-alkyl moiety substituted with one or more moieties selected from the group —Y—X1 or —Y-L-Y1—X1; form a ring having at least 5 members, wherein the ring may be substituted or interrupted by one or more hetero atom(s) and/or functional group(s); or …